MD1663C2 - Compoziţie şi metode pentru modularea reacţiei sexuale umane şi tratamentul impotenţei - Google Patents
Compoziţie şi metode pentru modularea reacţiei sexuale umane şi tratamentul impotenţeiInfo
- Publication number
- MD1663C2 MD1663C2 MD98-0007A MD980007A MD1663C2 MD 1663 C2 MD1663 C2 MD 1663C2 MD 980007 A MD980007 A MD 980007A MD 1663 C2 MD1663 C2 MD 1663C2
- Authority
- MD
- Moldova
- Prior art keywords
- impotency
- composition
- treatment
- methods
- sexual activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Invenţia se referă la medicină.Esenţa invenţiei constă în aceea că per os se administrează compoziţie, conţinând un vasodilatator, în formă de tablete, prafuri şi pastile cu o perioadă de dezintegrare de până la 20 min.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/431,145 US5731339A (en) | 1995-04-28 | 1995-04-28 | Methods and formulations for modulating the human sexual response |
PCT/US1996/005816 WO1996033705A1 (en) | 1995-04-28 | 1996-04-26 | Methods and formulations for modulating the human sexual response |
Publications (3)
Publication Number | Publication Date |
---|---|
MD980007A MD980007A (ro) | 1999-07-31 |
MD1663B2 MD1663B2 (ro) | 2001-05-31 |
MD1663C2 true MD1663C2 (ro) | 2001-11-30 |
Family
ID=23710676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MD98-0007A MD1663C2 (ro) | 1995-04-28 | 1996-04-26 | Compoziţie şi metode pentru modularea reacţiei sexuale umane şi tratamentul impotenţei |
Country Status (35)
Country | Link |
---|---|
US (6) | US5731339A (ro) |
EP (2) | EP0767660B1 (ro) |
JP (2) | JP3469901B2 (ro) |
KR (1) | KR100363056B1 (ro) |
CN (1) | CN101816638A (ro) |
AR (1) | AR001739A1 (ro) |
AT (1) | ATE185695T1 (ro) |
AU (1) | AU710111B2 (ro) |
BG (1) | BG63071B1 (ro) |
BR (1) | BR9604983A (ro) |
CA (1) | CA2219502C (ro) |
CZ (1) | CZ294350B6 (ro) |
DE (1) | DE69604762T2 (ro) |
DK (1) | DK0767660T3 (ro) |
EE (1) | EE03472B1 (ro) |
ES (1) | ES2140847T3 (ro) |
GR (1) | GR3032182T3 (ro) |
HU (1) | HU222044B1 (ro) |
IL (1) | IL117871A (ro) |
IS (1) | IS4598A (ro) |
LT (1) | LT4404B (ro) |
LV (1) | LV12038B (ro) |
MD (1) | MD1663C2 (ro) |
NO (1) | NO314746B1 (ro) |
NZ (1) | NZ307020A (ro) |
PL (1) | PL185528B1 (ro) |
PT (1) | PT767660E (ro) |
RO (1) | RO116866B1 (ro) |
RU (2) | RU2239424C2 (ro) |
SI (1) | SI9620058A (ro) |
SK (1) | SK283847B6 (ro) |
TR (2) | TR199701260T1 (ro) |
UA (1) | UA70277C2 (ro) |
WO (1) | WO1996033705A1 (ro) |
ZA (1) | ZA963380B (ro) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5731339A (en) * | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
US6387407B1 (en) | 1995-09-29 | 2002-05-14 | L.A.M. Pharmaceutical Corporation | Topical drug preparations |
US5897880A (en) | 1995-09-29 | 1999-04-27 | Lam Pharmaceuticals, Llc. | Topical drug preparations |
US6036977A (en) * | 1995-09-29 | 2000-03-14 | L.A.M. Pharmaceutical Corp. | Drug preparations for treating sexual dysfunction |
US6251436B1 (en) | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
US6258032B1 (en) * | 1997-01-29 | 2001-07-10 | William M. Hammesfahr | Method of diagnosis and treatment and related compositions and apparatus |
US20050065161A1 (en) * | 1996-02-02 | 2005-03-24 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
US6469065B1 (en) | 1996-02-02 | 2002-10-22 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use |
US6294517B1 (en) | 1996-02-02 | 2001-09-25 | Nitromed, Inc. | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
US20020143007A1 (en) * | 1996-02-02 | 2002-10-03 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
US6323211B1 (en) * | 1996-02-02 | 2001-11-27 | Nitromed, Inc. | Compositions and methods for treating sexual dysfunctions |
US6432401B2 (en) * | 2000-05-12 | 2002-08-13 | Novalar Pharmaceuticals, Inc. | Local anesthetic methods and kits |
US5958926A (en) * | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
USRE37234E1 (en) | 1996-11-01 | 2001-06-19 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses |
GR1002847B (el) | 1997-05-06 | 1998-01-27 | Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως | |
CN1262622A (zh) * | 1997-05-19 | 2000-08-09 | 佐纳根有限公司 | 调节人性反应的联合治疗 |
US20030004170A1 (en) * | 1997-05-19 | 2003-01-02 | Zonagen, Inc. | Combination therapy for modulating the human sexual response |
EP0998274B1 (en) | 1997-06-23 | 2006-01-18 | Cellegy Pharmaceuticals, Inc | Microdose therapy of vascular conditions by no donors |
WO1999002147A1 (en) | 1997-07-09 | 1999-01-21 | Androsolutions, Inc. | Improved methods and compositions for treating male erectile dysfunction |
US6103765A (en) * | 1997-07-09 | 2000-08-15 | Androsolutions, Inc. | Methods for treating male erectile dysfunction |
US6399618B1 (en) | 1997-07-09 | 2002-06-04 | Cardiome Pharma Corp | Compositions and methods for modulating sexual activity |
US5947901A (en) | 1997-09-09 | 1999-09-07 | Redano; Richard T. | Method for hemodynamic stimulation and monitoring |
US6593369B2 (en) | 1997-10-20 | 2003-07-15 | Vivus, Inc. | Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
US20050070516A1 (en) * | 1997-10-28 | 2005-03-31 | Vivus Inc. | As-needed administration of an androgenic agent to enhance female desire and responsiveness |
JP2001520999A (ja) | 1997-10-28 | 2001-11-06 | アシビ, エルエルシー | 女性の性的機能不全の処置 |
US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
US6169914B1 (en) | 1998-01-13 | 2001-01-02 | Urometrics, Inc. | Devices and methods for monitoring female arousal |
FR2774593B1 (fr) * | 1998-02-12 | 2000-05-05 | Philippe Gorny | Obtention d'un medicament destine a combattre les dysfonctions sexuelles feminines |
WO1999059584A1 (en) * | 1998-05-20 | 1999-11-25 | Schering Corporation | Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction |
US6011043A (en) * | 1998-06-19 | 2000-01-04 | Schering Corporation | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction |
US6525100B1 (en) | 1998-08-03 | 2003-02-25 | W. Jerry Easterling | Composition and method for treating peyronie's disease and related fibrotic tissue disorders |
US6627663B2 (en) | 1998-08-03 | 2003-09-30 | W. Jerry Easterling | Noninvasive method for treating hemangiomas through transdermal delivery of calcium channel blocker agents and medicament for use in such method |
US6031005A (en) * | 1998-08-03 | 2000-02-29 | Easterling; W. Jerry | Composition and method for treating Peyronie's disease and related connective tissue disorders |
US20040170675A1 (en) * | 1998-08-03 | 2004-09-02 | Easterling W. Jerry | Noninvasive method for treating cellulite through transdermal delivery of calcium channel blocker agents and medicament for use in such method |
GR1003199B (el) * | 1998-08-14 | 1999-09-01 | Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες | |
EP1235563A2 (en) * | 1998-08-26 | 2002-09-04 | Queen's University At Kingston | Use of anti(w)pressor agents for vascular remodeling in genital dysfunction |
US6482426B1 (en) | 1998-09-17 | 2002-11-19 | Zonagen, Inc. | Compositions for the treatment of male erectile dysfunction |
US6706682B2 (en) * | 1999-01-21 | 2004-03-16 | The Trustees Of Columbia University In The City Of New York | Uses of vascular endothelial growth factor in the treatment of erectile dysfunction |
US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
EP1161255A4 (en) * | 1999-03-08 | 2002-07-17 | Merck & Co Inc | METHOD AND MEANS FOR TREATING ERECTILE DYSFUNCTION |
EP1220666A2 (en) * | 1999-04-06 | 2002-07-10 | Zonagen, Inc. | Methods for modulating the human sexual response |
JP2002543128A (ja) | 1999-04-30 | 2002-12-17 | リリー アイコス リミテッド ライアビリティ カンパニー | 雌性覚醒障害の処置 |
IT1312310B1 (it) | 1999-05-07 | 2002-04-15 | Recordati Ind Chimica E Farma | Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale |
US20010003120A1 (en) * | 1999-05-14 | 2001-06-07 | M. D. Robert Hines | Method for treating erectile dysfunction |
US6916845B2 (en) * | 1999-06-17 | 2005-07-12 | Zhongcheng Xin | Method for prevention and treatment of male and female sexual dysfunction |
US6730065B1 (en) * | 2000-09-15 | 2004-05-04 | Ocularis Pharma, Inc. | Night vision composition |
US6399591B1 (en) * | 2000-01-19 | 2002-06-04 | Yung-Shin Pharmaceutical Ind. Co., Ltd. | Chargeable pharmaceutical tablets |
US6730691B1 (en) | 2000-02-10 | 2004-05-04 | Miles A. Galin | Uses of alpha adrenergic blocking agents |
EP1328281B1 (en) | 2000-06-27 | 2007-08-15 | Qualilife Pharmaceuticals Inc. | Compositions and methods for treating females sexual response |
BRPI0003386B8 (pt) * | 2000-08-08 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
KR20020020536A (ko) * | 2000-09-09 | 2002-03-15 | 장우영 | 발기유발제 |
US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
US20060211753A1 (en) * | 2000-11-03 | 2006-09-21 | Ocularis Pharma, Inc. | Method and composition which reduces stimulation of muscles which dilate the eye |
US20020107230A1 (en) * | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
US6987129B2 (en) | 2001-03-06 | 2006-01-17 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
US20020172712A1 (en) * | 2001-03-19 | 2002-11-21 | Alan Drizen | Antiemetic, anti-motion sustained release drug delivery system |
US20030138494A1 (en) * | 2001-05-15 | 2003-07-24 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
CA2457433A1 (en) | 2001-08-10 | 2003-02-20 | Molecular Design International Inc. | Novel alpha adrenergic agents |
AR036674A1 (es) * | 2001-08-28 | 2004-09-29 | Schering Corp | Inhibidores de fosfodiesterasa v de guanina de policiclicos, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos para tratar desordenes fisiologicos |
GB0130704D0 (en) * | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | New use |
AU2003286555A1 (en) * | 2002-10-22 | 2004-05-13 | Harbor-Ucla Research And Education Institute | Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases |
US8133903B2 (en) * | 2003-10-21 | 2012-03-13 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
CN100336506C (zh) * | 2004-04-23 | 2007-09-12 | 北京科信必成医药科技发展有限公司 | 甲磺酸酚妥拉明口腔崩解片及其制备方法 |
NZ551356A (en) * | 2004-05-11 | 2009-09-25 | Emotional Brain Bv | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
CA2568640C (en) * | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
US20060167022A1 (en) * | 2004-09-08 | 2006-07-27 | Woodward John R | Method of female sexual enhancement |
US20060052402A1 (en) * | 2004-09-08 | 2006-03-09 | Woodward John R | Method of female sexual enhancement |
US20080119445A1 (en) * | 2004-09-08 | 2008-05-22 | Woodward John R | Methods of female sexual enhancement |
US20060276442A1 (en) * | 2004-09-08 | 2006-12-07 | Woodward John R | Methods of female sexual enhancement |
US20060252734A1 (en) * | 2004-09-08 | 2006-11-09 | Woodward John R | Methods of female sexual enhancement |
ES2339577T3 (es) * | 2004-10-18 | 2010-05-21 | Polymun Scientific Immunbiologische Forschung Gmbh | Composicion liposomal que contiene un principio activo para la relajacion de la musculatura lisa, preparacion de dicha composicion y su uso terapeutico. |
WO2006084082A1 (en) * | 2005-02-03 | 2006-08-10 | Duramed Pharmaceuticals, Inc. | Compositions of unconjugated estrogens and methods for their use |
US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
ZA200803087B (en) | 2005-10-12 | 2009-11-25 | Unimed Pharmaceuticals Llc | Improved testosterone gel and method of use |
EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
EP1925307A1 (en) * | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
EP2157937B1 (en) | 2007-06-04 | 2017-03-22 | Sequent Medical, Inc. | Devices for treatment of vascular defects |
CA2893761C (en) * | 2012-12-05 | 2021-03-02 | Ge Nutrients, Inc. | Use of fenugreek extract to enhance female libido |
AU2014212275B2 (en) | 2013-02-01 | 2018-09-06 | Ocuphire Pharma, Inc. | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance |
ES2762153T3 (es) | 2013-02-01 | 2020-05-22 | Ocuphire Pharma Inc | Soluciones oftálmicas acuosas de fentolamina y usos médicos de las mismas |
CN104013588A (zh) * | 2014-04-14 | 2014-09-03 | 杨荣辰 | 一种甲磺酸酚妥拉明分散片及其制备方法 |
JP6483244B2 (ja) * | 2015-04-17 | 2019-03-13 | 株式会社山田養蜂場本社 | 蜂の子を含有する滋養強壮剤 |
WO2017100324A1 (en) * | 2015-12-10 | 2017-06-15 | Repros Therapeutics Inc. | Combination therapy for treating female hypoactive sexual desire disorders |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
SG11202104094YA (en) | 2018-10-26 | 2021-05-28 | Ocuphire Pharma Inc | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders |
CN115368310A (zh) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3943246A (en) * | 1972-07-10 | 1976-03-09 | Sandoz Ltd. | Organic compounds |
US4127118A (en) * | 1977-03-16 | 1978-11-28 | Alvaro Latorre | Method of effecting and enhancing an erection |
US4139617A (en) * | 1974-05-13 | 1979-02-13 | Richardson-Merrell Inc. | 19-Oxygenated-androst-5-enes for the enhancement of libido |
US4530920A (en) * | 1983-11-07 | 1985-07-23 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist |
US4801587A (en) * | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
US4863911A (en) * | 1986-08-04 | 1989-09-05 | University Of Florida | Method for treating male sexual dysfunction |
US4885173A (en) * | 1985-05-01 | 1989-12-05 | University Of Utah | Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities |
US5059603A (en) * | 1989-06-12 | 1991-10-22 | Centuries Laboratories, Inc. | Method and composition for treating impotence |
US5065744A (en) * | 1989-06-16 | 1991-11-19 | Zusmanovsky Zinovy A | Device for treatment of sexual impotence in human males |
US5079018A (en) * | 1989-08-14 | 1992-01-07 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
WO1995005172A1 (en) * | 1993-08-13 | 1995-02-23 | Zonagen, Inc. | Methods for modulating the human sexual response |
CA2219502A1 (en) * | 1995-04-28 | 1996-10-31 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2503059A (en) * | 1950-04-04 | Nxchj | ||
US3937834A (en) * | 1970-10-02 | 1976-02-10 | Ciba-Geigy Corporation | Pharmaceutical preparations |
GB1500300A (en) * | 1975-01-06 | 1978-02-08 | Ciba Geigy Ag | Pharmaceutical preparation for the treatment of circulatory disorders |
NZ179623A (en) * | 1975-01-06 | 1978-03-06 | Ciba Geigy | Pharmaceutical preparation containing a beta-receptor blocking compound, a compound regulating thrombocyte function and optionally an alpha-receptor blocking compund |
DE2965278D1 (en) * | 1978-07-21 | 1983-06-01 | Ciba Geigy Ag | Pharmaceutical mixtures containing an amantadine compound |
US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
EP0152379A3 (de) * | 1984-02-15 | 1986-10-29 | Ciba-Geigy Ag | Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen |
US5256652A (en) * | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
SE463851B (sv) * | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
FR2649613B1 (fr) * | 1989-07-11 | 1991-09-27 | Virag Ronald | Medicament vaso-actif |
US5236904A (en) * | 1989-09-18 | 1993-08-17 | Senetek, Plc | Erection-inducing methods and compositions |
US5270323A (en) * | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
US5399581A (en) * | 1990-12-26 | 1995-03-21 | Laragh; John H. | Method and compositions for treatment of sexual impotence |
US5298261A (en) * | 1992-04-20 | 1994-03-29 | Oregon Freeze Dry, Inc. | Rapidly distintegrating tablet |
-
1995
- 1995-04-28 US US08/431,145 patent/US5731339A/en not_active Expired - Lifetime
-
1996
- 1996-04-11 IL IL11787196A patent/IL117871A/xx not_active IP Right Cessation
- 1996-04-26 HU HU9802825A patent/HU222044B1/hu active IP Right Grant
- 1996-04-26 EP EP96913174A patent/EP0767660B1/en not_active Expired - Lifetime
- 1996-04-26 WO PCT/US1996/005816 patent/WO1996033705A1/en active IP Right Grant
- 1996-04-26 RU RU2000100756/15A patent/RU2239424C2/ru active
- 1996-04-26 UA UA97105248A patent/UA70277C2/uk unknown
- 1996-04-26 DE DE69604762T patent/DE69604762T2/de not_active Expired - Lifetime
- 1996-04-26 SI SI9620058A patent/SI9620058A/sl unknown
- 1996-04-26 EE EE9700276A patent/EE03472B1/xx not_active IP Right Cessation
- 1996-04-26 SK SK1458-97A patent/SK283847B6/sk unknown
- 1996-04-26 CZ CZ19973393A patent/CZ294350B6/cs not_active IP Right Cessation
- 1996-04-26 AR AR33632696A patent/AR001739A1/es not_active Application Discontinuation
- 1996-04-26 KR KR1019970707656A patent/KR100363056B1/ko not_active IP Right Cessation
- 1996-04-26 PT PT96913174T patent/PT767660E/pt unknown
- 1996-04-26 DK DK96913174T patent/DK0767660T3/da active
- 1996-04-26 BR BR9604983A patent/BR9604983A/pt not_active Application Discontinuation
- 1996-04-26 JP JP53273896A patent/JP3469901B2/ja not_active Expired - Lifetime
- 1996-04-26 RU RU97119646/14A patent/RU2177786C2/ru active
- 1996-04-26 PL PL96323087A patent/PL185528B1/pl unknown
- 1996-04-26 NZ NZ307020A patent/NZ307020A/xx not_active IP Right Cessation
- 1996-04-26 TR TR97/01260T patent/TR199701260T1/xx unknown
- 1996-04-26 ES ES96913174T patent/ES2140847T3/es not_active Expired - Lifetime
- 1996-04-26 MD MD98-0007A patent/MD1663C2/ro unknown
- 1996-04-26 CN CN200910151335A patent/CN101816638A/zh active Pending
- 1996-04-26 CA CA002219502A patent/CA2219502C/en not_active Expired - Lifetime
- 1996-04-26 TR TR1999/01973T patent/TR199901973T2/xx unknown
- 1996-04-26 AT AT96913174T patent/ATE185695T1/de active
- 1996-04-26 AU AU55768/96A patent/AU710111B2/en not_active Expired
- 1996-04-26 EP EP99114470A patent/EP0962225A3/en not_active Withdrawn
- 1996-04-26 RO RO97-01998A patent/RO116866B1/ro unknown
- 1996-04-29 ZA ZA963380A patent/ZA963380B/xx unknown
-
1997
- 1997-10-24 IS IS4598A patent/IS4598A/is unknown
- 1997-10-27 LV LVP-97-209A patent/LV12038B/en unknown
- 1997-10-27 NO NO19974965A patent/NO314746B1/no not_active IP Right Cessation
- 1997-10-28 LT LT97-168A patent/LT4404B/lt not_active IP Right Cessation
- 1997-10-29 US US08/959,672 patent/US5981563A/en not_active Expired - Lifetime
- 1997-10-31 BG BG102010A patent/BG63071B1/bg unknown
-
1998
- 1998-03-10 US US09/037,898 patent/US6100286A/en not_active Expired - Lifetime
-
1999
- 1999-07-28 US US09/362,518 patent/US6166061A/en not_active Expired - Lifetime
- 1999-07-28 US US09/362,825 patent/US6051594A/en not_active Expired - Lifetime
- 1999-07-28 US US09/362,486 patent/US6124337A/en not_active Expired - Lifetime
- 1999-12-17 GR GR990403268T patent/GR3032182T3/el unknown
-
2001
- 2001-07-16 JP JP2001215110A patent/JP4531301B2/ja not_active Expired - Lifetime
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3943246A (en) * | 1972-07-10 | 1976-03-09 | Sandoz Ltd. | Organic compounds |
US4139617A (en) * | 1974-05-13 | 1979-02-13 | Richardson-Merrell Inc. | 19-Oxygenated-androst-5-enes for the enhancement of libido |
US4127118B1 (en) * | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
US4127118A (en) * | 1977-03-16 | 1978-11-28 | Alvaro Latorre | Method of effecting and enhancing an erection |
US4530920A (en) * | 1983-11-07 | 1985-07-23 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist |
US4885173A (en) * | 1985-05-01 | 1989-12-05 | University Of Utah | Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities |
US4863911A (en) * | 1986-08-04 | 1989-09-05 | University Of Florida | Method for treating male sexual dysfunction |
US4801587A (en) * | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
US5059603A (en) * | 1989-06-12 | 1991-10-22 | Centuries Laboratories, Inc. | Method and composition for treating impotence |
US5065744A (en) * | 1989-06-16 | 1991-11-19 | Zusmanovsky Zinovy A | Device for treatment of sexual impotence in human males |
US5079018A (en) * | 1989-08-14 | 1992-01-07 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
WO1995005172A1 (en) * | 1993-08-13 | 1995-02-23 | Zonagen, Inc. | Methods for modulating the human sexual response |
US5565466A (en) * | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
CA2219502A1 (en) * | 1995-04-28 | 1996-10-31 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
US5981563A (en) * | 1995-04-28 | 1999-11-09 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
US6051594A (en) * | 1995-04-28 | 2000-04-18 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
Non-Patent Citations (7)
Title |
---|
Althof, S. E. et al. Sexual, psychological, and marital impact of self-injection of papaverine and phentolamine; a long-term prospective study. J. Sex & Marital Ther., vol.17(2), 1991, p. 101-112 * |
Brindley, G. S. Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis. Br. J. Pharmac., vol. 87, 1986, p. 495-500 * |
Brindley, G. S., Cavernosal Alpha-Blockade. A New Technique for Investigating and treating Erectile Impotence. Brit. J. Psychiat., vol.143, 1983, p. 332-337 * |
Corriere, Jr. et al. Development of Fibrotic Penile Lesions Secondary to the Intracorporeal Injection of Vasoactive Agents. J. Urol., vol. 140, 1988, p. 615-617 * |
Gwinup, G. Oral Phentolamine in Nonspecific Erectile Insufficiency. Ann. Int. Med., 15 Jul. 1988, p.162-163 * |
Sonda, L. P. et al. The Role of Yohimbine for the Treatment of Erectile Impotence. J. Sex & Marital Ther., vol. 16(1), 1990, p.15-21 * |
Zorgniotti, A. W. et al. Auto-Injection of the Corpus Cavernosum with a Vasoactive Drug Combination for Vasculogenic Impotence. J. Urol., vol.133, 1985, p. 39-41 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD1663C2 (ro) | Compoziţie şi metode pentru modularea reacţiei sexuale umane şi tratamentul impotenţei | |
AU5876596A (en) | Oral dosage and method for treating painful conditions of th e oral cavity | |
IS4083A (is) | Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja | |
ID24901A (id) | Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh | |
GEP20022783B (en) | Method of Preventing and Delaying Onset of Alzheimer's Disease and Composition Therefor | |
EP0209689A3 (en) | Use of tetrahydrobiopterins in the treatment of infantile autism | |
IL112518A0 (en) | Thyroid hormone fast dispersing pharmaceutical composition | |
IL103303A (en) | Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain | |
BG103647A (en) | Cisplatina containing microgranules | |
MY164077A (en) | Compositions and uses of et743 for treating cancer | |
UA32457C2 (uk) | Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм | |
ZA95679B (en) | Products containing G-CSF and TNF binding protein | |
PL338673A1 (en) | Application of fanquinone in treating alzheimer disease | |
HK1037980A1 (en) | Use of selegiline or desmethylselegiline for the manufacture of a medicament for treating wounds, burns or photodamage. | |
GB2331926A (en) | Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine | |
IL118218A0 (en) | Terpenoidic derivatives and pharmaceutical compositions containing them | |
HUT70521A (en) | Process to prepare pharmaceutical comps. again amyloidosis | |
GR3034062T3 (en) | Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease | |
MD518G2 (ro) | Remediu pentru sporirea rezistenţei organismului uman | |
MD1469G2 (ro) | Metodă de tratament al şocului combustional | |
MD1664F1 (ro) | Metoda de profilaxie a recidivelor bolii ulceroase | |
PL325557A1 (en) | Agent for use in prophylactics and/or treatmet of human and animal hair loss | |
MX9706188A (es) | Inhibicion de la angiogenesis usando interleucina 12. | |
UA29025A (uk) | Спосіб лікування ендокринної неплідності | |
GR1003066B (el) | Καλλυντικα σκευασματα και φαρμακα που προερχονται απο τη χρηση των δραστικων συστατικων του φυτου hypericum perforatum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD99 | Pending application |